Gene variant reduces cholesterol by two mechanisms

High levels of low-density lipoprotein (LDL) cholesterol increases the risk for coronary heart disease.

A variant in the encoding the protein sortilin is associated with reduced plasma LDL levels and a decreased risk of heart attack.

This variant results in markedly higher sortilin in liver.

Dr. Daniel Rader and colleagues at the University of Pennsylvania in Philadelphia have uncovered a two-pronged mechanism for the change in LDL observed.

Using a mouse model system, the Rader team found that increased liver sortilin is responsible for reducing secretion of APOB, a protein that transports LDL to tissue, and also triggers LDL breakdown.

Both of these effects were dependent on a cellular process known as lysosomal targeting.

Their data provide functional evidence that genetically-increased hepatic sortilin in humans reduces LDL by increasing LDL degradation, thus removing LDL from circulation, as well as decreasing APOB.

More information: Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism, Journal of Clinical Investigation.

add to favorites email to friend print save as pdf

Related Stories

Bad cholesterol inhibits the breakdown of peripheral fat

Nov 20, 2008

The so called bad cholesterol (LDL) inhibits the breakdown of fat in cells of peripheral deposits, according to a study from the Swedish medical university Karolinska Institutet. The discovery reveals a novel function of ...

Recommended for you

Better living through mitochondrial derived vesicles

17 hours ago

(Medical Xpress)—As principal transformers of bacteria, organelles, synapses, and cells, vesicles might be said to be the stuff of life. One need look no further than the rapid rise to prominence of The ...

Zebrafish help to unravel Alzheimer's disease

18 hours ago

New fundamental knowledge about the regulation of stem cells in the nerve tissue of zebrafish embryos results in surprising insights into neurodegenerative disease processes in the human brain. A new study by scientists at ...

Engineering new bone growth

21 hours ago

MIT chemical engineers have devised a new implantable tissue scaffold coated with bone growth factors that are released slowly over a few weeks. When applied to bone injuries or defects, this coated scaffold ...

User comments